Cytek Biosciences (CTKB) Net Cash Flow (2020 - 2026)

Cytek Biosciences' Net Cash Flow history runs 7 years deep, the most recent figure standing at -$25.8 million for Q1 2026.

• Quarterly Net Cash Flow fell 1064.74% year-over-year to -$25.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$31.6 million (up 58.1% YoY) and the FY2025 annual result came in at -$8.0 million, up 89.1% from the prior year.
• Net Cash Flow was -$25.8 million for Q1 2026 at Cytek Biosciences, down from -$3.8 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $30.6 million in Q3 2023 and bottomed at -$166.0 million in Q1 2023.
• A 5-year average of -$17.7 million and a median of -$3.8 million in 2025 frame the typical range for Net Cash Flow.
• Annual changes were most pronounced in 2023 — Net Cash Flow tumbled 8656.12% — and 2024, when it jumped 4076.28%.
• Cytek Biosciences' Net Cash Flow stood at -$41.0 million in 2022, then soared by 111.76% to $4.8 million in 2023, then sank by 1449.0% to -$65.1 million in 2024, then soared by 94.1% to -$3.8 million in 2025, then tumbled by 572.94% to -$25.8 million in 2026.
• Business Quant data shows CTKB's Net Cash Flow at -$25.8 million in Q1 2026, -$3.8 million in Q4 2025, and $17.0 million in Q3 2025.